← Back to headlines
BTIG Reaffirms Buy Rating for Praxis Precision Medicines
BTIG has reiterated its 'Buy' rating for Praxis Precision Medicines (PRAX), indicating continued confidence in the company's stock performance and prospects.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Aon Agrees to $17 Billion Acquisition of Rival USI Insurance
34m ago
Glacier Bancorp Appoints Byron Pollan as New Chief Financial Officer
42m ago
Prediction Platform Kalshi Bans Former Congressman George Santos for Life
59m ago
U.S. Treasury Yields Surge as Fed Official Signals Support for Rate Hike
1h ago